common.study.topics.clinical

Experimenta Treatment for Advanced or Metastatic Cancers

common.study.values.description

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum- tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - ZW49

Dose Escalation: ZW49 administration IV Q2W or Q3W at dose levels determined by the SMC Expansion: MTD(s) or RD(s) identified in the dose-escalation part of the study

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

common.study.values.clinical-trial-id

NCT03821233

participant.views.study.view.id

dNkWKe